Cargando…
The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 wa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035241/ https://www.ncbi.nlm.nih.gov/pubmed/35461222 http://dx.doi.org/10.1186/s12885-022-09588-z |
_version_ | 1784693254226182144 |
---|---|
author | Ye, Shuang Zhou, Shuling Zhong, Siyuan Shan, Boer Jiang, Wenhua Yang, Wentao Cai, Xu Yang, Huijuan |
author_facet | Ye, Shuang Zhou, Shuling Zhong, Siyuan Shan, Boer Jiang, Wenhua Yang, Wentao Cai, Xu Yang, Huijuan |
author_sort | Ye, Shuang |
collection | PubMed |
description | BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 was performed on whole section slides, and the results were correlated with clinicopathologic variables. RESULTS: A total of 108 cases were included in the present study with a median age of 52 years at first diagnosis. Early-stage disease and platinum-sensitive recurrence accounted for 62.3 and 69.6%, respectively, of the total cases. Overall, the estimated 5-year overall survival was 70.3 and 20.7% in patients with early- and late-stage tumors, respectively. Deficient MMR was identified in 5.6% (6/108) of the cohort and included MSH2/MSH6 (n = 4) and MLH1/PMS2 (n = 2). The average age of the six patients with deficient MMR was 45.6 years, and the rate of MMR-deficient tumors in women ≤50 years was relatively higher than that in women over 50 years (10.0% vs. 2.9%; P = 0.266). Half of the patients with deficient MMR were diagnosed with synchronous (endometrial or colorectal) and metachronous (endometrial) cancer, which was significantly more than their intact counterparts (P = 0.002). All six patients with deficient MMR had early-stage tumors, and the majority (83.3%) were platinum sensitive. The median progression-free survival was slightly higher in patients with defective MMR expression than in their intact counterparts (30 months vs. 27 months), but significance was not achieved (P = 0.471). CONCLUSIONS: Young ovarian CCC patients with concurrent diagnosis of endometrial and colorectal cancer are more likely to have MMR-deficient tumors, thereby warranting additional studies to determine whether patients harboring MMR abnormalities have a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09588-z. |
format | Online Article Text |
id | pubmed-9035241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90352412022-04-25 The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma Ye, Shuang Zhou, Shuling Zhong, Siyuan Shan, Boer Jiang, Wenhua Yang, Wentao Cai, Xu Yang, Huijuan BMC Cancer Research BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 was performed on whole section slides, and the results were correlated with clinicopathologic variables. RESULTS: A total of 108 cases were included in the present study with a median age of 52 years at first diagnosis. Early-stage disease and platinum-sensitive recurrence accounted for 62.3 and 69.6%, respectively, of the total cases. Overall, the estimated 5-year overall survival was 70.3 and 20.7% in patients with early- and late-stage tumors, respectively. Deficient MMR was identified in 5.6% (6/108) of the cohort and included MSH2/MSH6 (n = 4) and MLH1/PMS2 (n = 2). The average age of the six patients with deficient MMR was 45.6 years, and the rate of MMR-deficient tumors in women ≤50 years was relatively higher than that in women over 50 years (10.0% vs. 2.9%; P = 0.266). Half of the patients with deficient MMR were diagnosed with synchronous (endometrial or colorectal) and metachronous (endometrial) cancer, which was significantly more than their intact counterparts (P = 0.002). All six patients with deficient MMR had early-stage tumors, and the majority (83.3%) were platinum sensitive. The median progression-free survival was slightly higher in patients with defective MMR expression than in their intact counterparts (30 months vs. 27 months), but significance was not achieved (P = 0.471). CONCLUSIONS: Young ovarian CCC patients with concurrent diagnosis of endometrial and colorectal cancer are more likely to have MMR-deficient tumors, thereby warranting additional studies to determine whether patients harboring MMR abnormalities have a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09588-z. BioMed Central 2022-04-23 /pmc/articles/PMC9035241/ /pubmed/35461222 http://dx.doi.org/10.1186/s12885-022-09588-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ye, Shuang Zhou, Shuling Zhong, Siyuan Shan, Boer Jiang, Wenhua Yang, Wentao Cai, Xu Yang, Huijuan The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title | The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title_full | The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title_fullStr | The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title_full_unstemmed | The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title_short | The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma |
title_sort | frequency and clinical implication of mismatch repair protein deficiency in chinese patients with ovarian clear cell carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035241/ https://www.ncbi.nlm.nih.gov/pubmed/35461222 http://dx.doi.org/10.1186/s12885-022-09588-z |
work_keys_str_mv | AT yeshuang thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT zhoushuling thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT zhongsiyuan thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT shanboer thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT jiangwenhua thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT yangwentao thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT caixu thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT yanghuijuan thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT yeshuang frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT zhoushuling frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT zhongsiyuan frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT shanboer frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT jiangwenhua frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT yangwentao frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT caixu frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma AT yanghuijuan frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma |